PSMA PET for the Staging and Management of Hepatocellular Carcinoma
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Sponsor: VA Office of Research and Development
You may qualify if…
- ✓ Adult patients age \>18 years from the VA medical system
- ✓ Treatment-naïve patients with HCC with BCLC B or C disease
You may not qualify if…
- ✕ Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging
- ✕ Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years
Where it's recruiting
West Los Angeles
Miami
Source: ClinicalTrials.gov · NCT07019844 · last updated 2026-06-26